Bayer's $66B Monsanto Buy To Face Tough Antitrust Scrutiny
German drug and chemical maker Bayer's $66 billion takeover of U.S. agrochemical company Monsanto is poised to draw intense antitrust scrutiny from regulators, particularly in the U.S. where megadeals are struggling...To view the full article, register now.
Already a subscriber? Click here to view full article